Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384423 | 0.93 | SLC6A2 (0.63) | SLC6A3SLC6A2SLC6A4KCNA5TSHR | |
| SCHEMBL2111803 | 0.93 | SLC6A2 (0.63) | SLC6A3SLC6A2SLC6A4KCNA5TSHR | |
| SCHEMBL6766141 | 0.93 | SLC6A2 (0.63) | SLC6A3SLC6A2SLC6A4KCNA5TSHR | |
| Hydrochloric Acid SCHEMBL1421214 | 0.91 | SLC6A2 (0.61) | SLC6A3SLC6A2SLC6A4KCNA5TSHR | |
| Hydrochloric Acid SCHEMBL4509965 | 0.91 | SLC6A2 (0.61) | SLC6A3SLC6A2SLC6A4KCNA5TSHR | |
| Hydrochloric Acid SCHEMBL7226415 | 0.91 | SLC6A2 (0.61) | SLC6A3SLC6A2SLC6A4KCNA5TSHR | |
| SCHEMBL6530520 | 0.90 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4KCNA5TSHR | |
| SCHEMBL6775380 | 0.90 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4KCNA5TSHR | |
| SCHEMBL6776456 | 0.90 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4KCNA5TSHR | |
| SCHEMBL10557226 | 0.90 | SLC6A2 (0.51) | SLC6A3SLC6A2SLC6A4TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11285151-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| EP-2776387-B1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | UNIV EMORY (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160002174-A1 | CXCR4 Antagonists for the Treatment of Medical Disorders | EMORY UNIVERSITY | 2016-01-07 | — | — | US | disclosed |
| US-9205085-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2776387-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | Emory University (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1838321-A4 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION | UNIV EMORY (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1838320-A4 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | UNIV EMORY (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1838321-A2 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION | EMORY UNIVERSITY (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1838320-A2 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20060264451-A1 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY | 2006-11-23 | — | — | US | disclosed |
| WO-2006074428-A2 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006074426-A2 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION | EMORY UNIVERSITY (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | SLC6A3 285/4885SLC6A2 217/4885SLC6A4 30/4885 |
| US-20060264451-A1 | CXCR4 antagonists for the treatment of HIV infection | CXCR4, CXCL12, CCR5 | SLC6A3 1051/4885SLC6A2 1395/4885SLC6A4 1541/4885 |
| US-11285151-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | SLC6A3 285/4885SLC6A2 217/4885SLC6A4 30/4885 |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | SLC6A3 285/4885SLC6A2 217/4885SLC6A4 30/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | SLC6A3 2508/4885SLC6A2 2808/4885SLC6A4 3721/4885 |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | SLC6A3 285/4885SLC6A2 217/4885SLC6A4 30/4885 |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | SLC6A3 285/4885SLC6A2 217/4885SLC6A4 30/4885 |
| US-20160002174-A1 | CXCR4 Antagonists for the Treatment of Medical Disorders | CXCR4, CXCL12, CXCR1 | SLC6A3 2508/4885SLC6A2 2808/4885SLC6A4 3721/4885 |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | SLC6A3 285/4885SLC6A2 217/4885SLC6A4 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.